RNA-Protein Interactions During Hepatitis C Virus Infection
RNA-Protein Interactions During Hepatitis C Virus Infection
批准号:
9317274
负责人:
Rebecca Lynn Adams
金额:
$5.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2019-07-31
关键词:
AffectAlpha CellAntisense RNAAntiviral AgentsAntiviral TherapyBasic ScienceBinding SitesCancer EtiologyCell Culture TechniquesCell physiologyCellsCessation of lifeChromatographyChronicCirrhosisClipComplexDevelopmentElementsGene ExpressionGenomeGenotypeGoalsHepatitis CHepatocyteImmunoprecipitationIn VitroInfectionInvestigationKnowledgeLeadLiver CirrhosisMalignant NeoplasmsMass Spectrum AnalysisMicroRNAsModelingMolecularMutationPeptide HydrolasesPharmaceutical PreparationsPharmacotherapyPhysiologicalPlayPopulationPrimary carcinoma of the liver cellsProtease DomainProteinsRNARNA BindingRNA HelicaseRNA Virus InfectionsRNA VirusesRNA analysisRNA-Protein InteractionRibonucleosidesRoleStructureTestingTranscriptTranslatingVaccinesViralViral GenomeViral ProteinsVirionVirusVirus DiseasesVirus ReplicationWorkbasecellular targetingcombatcrosslinkexperimental studyfollow-uphelicasein vivoknock-downliver developmentliver transplantationmetaplastic cell transformationmortalitymutantnovelpreventresearch studytranscriptome sequencingviral RNAviral detection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Hepatitis C Virus (HCV) is a RNA virus that currently infects three percent of the world's population. By
chronically infecting hepatocytes, HCV leads to severe physiological changes of host cells. This often leads to
liver cirrhosis, which is the leading cause for development of hepatocellular carcinoma (HCC) and need for
liver transplantation. HCC is the second leading cause of cancer-related deaths worldwide, and current
treatment of HCC is indirect and ineffective. Vaccines have not been successfully developed to prevent HCV
infection, and direct-acting antiviral (DAA) therapy has only recently become successful, largely thanks to basic
science research studying molecular aspects of HCV infection.
HCV is a RNA-only virus, and recent advances in the study and analysis of RNA has lead to a revolution in
understanding the complex role that diverse RNAs play in cells. This proposal seeks a molecular
understanding of RNA-protein interactions between the virus and host cell during HCV infection using state-of-
the-art approaches.
In Aim 1, I will analyze the in vivo RNA targets of the HCV bi-functional protease/RNA helicase, NS3. Although
NS3 is a target of current DAA therapy, no studies have analyzed what the RNA substrates for NS3 helicase
activity are. It is presumed that NS3 targets viral RNA, but it is unknown whether the helicase impacts cellular
gene expression. To resolve these unknowns, I will perform PAR-Clip on NS3. PAR-Clip permits unambiguous
identification of regions of RNA that directly interact with proteins, and I will use a variety of mutants and/or
drugs to probe the consequences of altering helicase or protease activity.
In Aim 2, I will test whether the HCV RNA genome interacts with cellular proteins. The Pyle lab has uncovered
conserved RNA structures that are required for normal HCV replication and infectivity. I will use RAP-MS to
uncover whether host cell proteins interact with these structures. Follow-up experiments will confirm direct
interactions and analyze the function of these interactions.
These approaches will inform how RNA-protein interactions impact viral replication and cellular physiology.
The ultimate goal of this work is to aid in the development of DAAs, uncover markers for HCC progression, and
discover aspects of infection that can inform the study of other RNA viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金